Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing

Serious liver injury has been reported with pirfenidone in the first year after initiation. MHRA advises liver function tests before starting treatment, monthly for the first 6 months and then every 3 months thereafter.

Source:

Medicines and Healthcare products Regulatory Agency